Source-grounded facts extracted from Jaguar Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jaguar Health, Inc. entered into Supply Agreement with Woodward Specialty LLC and Future Pak, LLC (effective 2026-01-12).
“Also on the Effective Date, Napo, Licensee and Future Pak entered into a manufacturing and supply agreement (the “Supply Agreement”)”
Jaguar Health, Inc. entered into License Agreement with Woodward Specialty LLC and Future Pak, LLC valued at $18 million (effective 2026-01-12).
“On January 12, 2026 (the “Effective Date”), Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned subsidiary of Jaguar Health, Inc., a Delaware corporation (the “Company”), and the Company, entered into a license agreement (the “License Agreement”) with Woodward Specialty LLC (the “Licensee”), an affiliate of Future Pak, LLC (“Future Pak”), and Future Pak”
Jaguar Health, Inc. issued up to an aggregate of 350,000 shares of warrant to two accredited investors for initial exercise price equal to $1.00 per share.
“of 350,000 shares (the “Warrant Shares”) of the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”), with an initial exercise price equal to $1.00 per share, subject to adjustment for reclassification of the Common Stock, non-cash dividend, stock split, reverse stock split or other similar transaction (the “Exercise Price”).”
Jaguar Health, Inc. issued convertible note to two accredited investors for $350,000 aggregate principal amount.
“the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”
Jaguar Health, Inc. issued 350,000 shares of warrant to two accredited investors for $350,000 aggregate principal amount of unsecured promissory notes.
“entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors. The Company will use the proceeds for working capital and other general”
Jaguar Health, Inc. entered into Securities Purchase Agreements with two accredited investors valued at $350,000 aggregate principal amount (effective 2026-01-06).
“On January 6, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”
Jaguar Health, Inc. entered into Securities Purchase Agreements with two accredited investors valued at $350,000 (effective 2026-01-05).
“On January 5, 2026 (the "Execution Date"), Jaguar Health, Inc. (the "Company") entered into securities purchase agreements (the "Securities Purchase Agreements") with two accredited investors (each, an "Investor"), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes”
Jaguar Health, Inc. entered into Securities Purchase Agreements with two accredited investors valued at $350,000 aggregate principal amount (effective 2026-01-06).
“On January 6, 2026 (the "Execution Date"), Jaguar Health, Inc. (the "Company") entered into securities purchase agreements (the "Securities Purchase Agreements") with two accredited investors (each, an "Investor"), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the "Notes") to such Investors.”
Jaguar Health, Inc. incurred loan of $350,000 aggregate principal amount with two accredited investors at 6% per annum maturing one month after issuance.
“On January 6, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”
Jaguar Health, Inc. incurred senior notes of $350,000 aggregate principal amount at 6% per annum maturing one month after issuance.
“On January 5, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”
Jaguar Health, Inc. incurred senior notes of $350,000 at 6% per annum maturing one month after issuance.
“On January 6, 2026 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with two accredited investors (each, an “Investor”), pursuant to which the Company issued $350,000 aggregate principal amount of unsecured promissory notes (collectively, the “Notes”) to such Investors.”
Jaguar Health, Inc. entered into Second Exchange Agreement with Iliad Research and Trading, L.P. (effective 2025-12-11).
“On December 11, 2025, the Company entered into another privately negotiated exchange agreement with Iliad (the “Second Exchange Agreement” and together with the First Exchange Agreement, collectively the “Exchange Agreements”), pursuant to which the Company issued (i) 40,000 shares of Common Stock (the “Second Exchange Shares” and together with the First Exchange Shares, collectively the “Exchange Shares”) and (ii) a pre-funded common stock purchase warrant to purchase 304,827 shares of Common Stock (the “Second Pre-Funded Warrant” and together with the First Pre-Funded Warrant, collectively the “Pre-Funded Warrants”) to Iliad in exchange for 16 shares of Series M Preferred Stock held by Iliad”
Jaguar Health, Inc. entered into First Exchange Agreement with Iliad Research and Trading, L.P. (effective 2025-12-09).
“On December 9, 2025, the Company entered into a privately negotiated exchange agreement with Iliad (the “First Exchange Agreement”), pursuant to which the Company issued (i) 400,000 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) and (ii) a pre-funded common stock purchase warrant to purchase 1,304,545 shares of Common Stock (the “First Pre-Funded Warrant”) to Iliad in exchange for 75 shares of Series M Preferred Stock held by Iliad”
Jaguar Health, Inc. issued 361,271 shares of common stock of common stock to Streeterville for 25 outstanding shares of Series M Preferred Stock.
“On November 17, 2025, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Exchange Agreement”), pursuant to which the Company issued an aggregate of 361,271 shares of the Company’s common stock, par value $0.0001 (the “Common Exchange Shares”) to Streeterville in exchange for 25 outstanding shares of Series M Preferred Stock held by Streeterville (the “Exchanged Preferred Shares”).”
Jaguar Health, Inc. amended loan with Streeterville Capital, LLC maturing April 1, 2026.
“On November 17, 2025, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “Note Amendment No. 2”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date (as amended, the “Note Purchase Agreement”). Pursuant to the Note Amendment No. 2, the maturity date of the Note is extended to April 1, 2026.”
Jaguar Health, Inc. amended debt with Streeterville Capital, LLC.
“On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the”
Jaguar Health, Inc. amended debt with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC).
“On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the”
Jaguar Health, Inc. amended debt with Iliad Research and Trading, L.P..
“On November 17, 2025, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments No. 3”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on April 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the”
Jaguar Health, Inc. incurred loan of $10,810,000 with Streeterville Capital, LLC at 8.00% per annum maturing 36 months following the date of issuance.
“the Company issued and sold to the Lender a secured promissory note in the original principal amount of $10,810,000”
Jaguar Health, Inc. issued 286,532 shares of common stock to a holder of royalty interest for $600,000 reduction.
“On September 30, 2025, Jaguar Health, Inc. (the “Company”) entered into a privately negotiated exchange agreement (the “Exchange Agreement”) with a holder of royalty interest in the Company. Pursuant to the Exchange Agreement, the Company issued 286,532 shares of common stock to such holder in exchange for a $600,000 reduction in the outstanding balance of the royalty interest held by such holder.”
Jaguar Health, Inc. issued 479,442 pre-funded warrants of warrant to Brown Stone Capital Limited for $1.56 minus $0.0001 per warrant.
“PIPE Financing On September 28, 2025, Jaguar Health, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with Brown Stone Capital Limited (the “ Investor ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement ”) (i) 161,583 shares (“ Shares ”) of the Company’s voting common stock, par value 0.0001 (the “ Common Stock ”) and (ii) 479,442 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase shares of Common Stock (the “ Pre-Funded Warrant Shares ” and together with the Shares and the Pre-Funded Warrants, the “ Securities ”).”
Jaguar Health, Inc. issued 161,583 shares of common stock to Brown Stone Capital Limited for $1.56 per share.
“shares of Common Stock (the “ Pre-Funded Warrant Shares ” and together with the Shares and the Pre-Funded Warrants, the “ Securities ”). The purchase price of the Shares is $1.56 per share and the purchase price for the Pre-Funded Warrants is $1.56 minus $0.0001. The Company intends to use the proceeds from the Private Placement for working capital and”
Jaguar Health, Inc. issued an aggregate of approximately 951 shares (the "Preferred Shares") of Series N Perpetual Preferred Stock of preferred stock to certain investors named therein (collectively, the "Purchasers") for aggregate purchase price of approximately $2.38 million.
“Shares”) of Series N Perpetual Preferred Stock, par value $0.0001 per share, of the Company (“Series N Preferred Stock”), for an aggregate purchase price of approximately $2.38 million (the “Private Placement”). The Private Placement closed on September 10, 2025, subject to customary closing conditions as set forth in the PIPE Purchase Agreements. The Company”
Jaguar Health, Inc.: Filed Series N Certificate of Designation for preferred stock (effective 2025-09-09).
“Series N Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the Private Placement, the Company agreed to issue shares of Series N Preferred Stock to the Purchasers. The preferences, rights, limitations and other matters relating to the Series N Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on September 9, 2025.”
Jaguar Health, Inc.: Filed Series M Certificate of Designation for preferred stock, establishing terms, rights, and preferences (effective 2025-06-27).
“The preferences, rights, limitations and other matters relating to the Series M Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on June 27, 2025.”
Jaguar Health, Inc. incurred convertible notes of approximately $2.57 million aggregate principal amount with Participating Investors at 6% per annum maturing January 30, 2026.
“On June 24, 2025, the Company entered into note exchange and warrant purchase agreements (the “Exchange Agreements”) with certain of the Original Investors (the “Participating Investors”), pursuant to which the Company agreed to (a) issue and sell (i) approximately $2.57 million aggregate principal amount of new 6% convertible promissory notes (the “Replacement Notes”), in exchange for the cancellation of the Original Notes held by the Participating Investors”
Jaguar Health, Inc.: Filed Series L Certificate of Designation with Delaware Secretary of State, establishing preferences, rights, and limitations of Series L Preferred Stock (effective 2025-05-14).
“The preferences, rights, limitations and other matters relating to the Series L Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on May 14, 2025.”
Jaguar Health, Inc. amended loan with Streeterville Capital, LLC maturing July 20, 2025.
“On January 29, 2025, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary ("Napo" and together with the Company, the "Borrower"), entered into an amendment (the "Note Amendment") with Streeterville Capital, LLC ("Streeterville") to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the "Note") issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date (as amended, the "Note Purchase Agreement"). Pursuant to Note Amendment, the maturity date of the Note is extended to July 20, 2025.”
Jaguar Health, Inc. incurred convertible notes of approximately $3.4 million aggregate principal amount with selected accredited investors at 6% per annum maturing three months after issuance.
“On March 26, 2025 (the “Execution Date”), Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with selected accredited investors (each, an “Investor”), pursuant to which the Company, in a private placement (the “Private Placement”), will issue approximately $3.4 million aggregate principal amount of convertible promissory notes (collectively, the “Notes”) to such Investors.”
Jaguar Health, Inc.: Filed Ninth Amendment to certificate of incorporation to effect a 1-for-25 reverse stock split of common stock (effective 2025-03-24).
“on March 18, 2025, the Company filed the Ninth Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective”
Jaguar Health, Inc.: Adopted a Certificate of Designation for Series K Junior Participating Preferred Stock in connection with a Rights Agreement (effective 2025-02-27).
“In connection with the adoption of the Rights Agreement, the Company has adopted a Certificate of Designation of Series K Junior Participating Preferred Stock (the “Certificate of Designation”). The Certificate of Designation was filed with the Secretary of State of the State of Delaware on February 27, 2025.”
Jaguar Health, Inc. amended loan of $6,220,812.50 with Streeterville Capital, LLC maturing January 20, 2026.
“On February 13, 2025, Jaguar Health, Inc. (the “Company”) and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “Note Amendment”) with Streeterville Capital, LLC (“Streeterville”) to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date (as amended, the “Note Purchase Agreement”). Pursuant to Note Amendment, the maturity date of the Note is extended to January 20, 2026.”
Jaguar Health, Inc. amended senior notes of $6,220,812.50 with Streeterville Capital, LLC maturing July 20, 2025.
“entered into an amendment (the “Note Amendment”) with Streeterville Capital, LLC (“Streeterville”) to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date”
Jaguar Health, Inc. shareholders approved Approve adjournment of Special Meeting to solicit additional proxies if necessary at the 2024-04-09 meeting.
“4. Proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1, 2, and 3 was approved by the stockholders by the following vote : For Against Abstained Broker Non- Votes 75,565,231 15,556,724 1,831,428 0”
Jaguar Health, Inc. shareholders approved Approve issuance of common stock pursuant to PIPE Warrant Exchange Agreements at the 2024-04-09 meeting.
“3. Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of 18,837,500 shares of Common Stock to certain accredited investors pursuant to the exchange agreements, dated February 27, 2024, between us and such investors (the “PIPE Warrant Exchange Agreements”), in exchange for certain warrants to acquire shares of Common Stock previously issued to such investors, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 55,863,424 10,656,130 710,848 25,722,981”
Jaguar Health, Inc. shareholders approved Approve issuance of common stock upon exchange of Series J Preferred Stock to certain accredited investors at the 2024-04-09 meeting.
“2. Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Company’s common stock upon exchange of shares of Series J Preferred Stock issued to certain accredited investors, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 34,430,429 11,120,770 1,024,155 25,722,981”
Jaguar Health, Inc. shareholders approved Approve amendment to Third Amended and Restated Certificate of Incorporation to effect reverse stock split at ratio of not less than 1-for-2 and not greater than 1-for-150 at the 2024-04-09 meeting.
“1. Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-2 and not greater than 1-for-150, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2025 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 73,520,240 19,147,290 285,853 0”
Jaguar Health, Inc.: Filed Certificate of Designation for Series J Preferred Stock with Delaware Secretary of State on March 1, 2024, effective upon filing, authorizing 200 shares of Series J Preferred Stock (effective 2024-03-01).
“Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series J Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the CVP Exchange Transaction, the Company agreed to issue shares of Series J Preferred Stock to Streeterville. The preferences, rights, limitations and other matters relating to the Series J Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on March 1, 2024. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing.”
Jaguar Health, Inc. entered into PIPE Warrant Exchange Agreements with the PIPE Investors (effective 2024-02-27).
“On February 27, 2024, each of the PIPE Investors entered into an exchange agreement with the Company (each, a “PIPE Warrant Exchange Agreement” and collectively, the “PIPE Warrant Exchange Agreements”).”
Jaguar Health, Inc. entered into Streeterville Exchange Agreement with Streeterville Capital, LLC (effective 2024-03-01).
“On March 1, 2024, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Exchange Agreement”), pursuant to which the Company issued an aggregate of 179.3822 shares of Series J Preferred Stock to Streeterville at an effective exchange price per share equal to the market price (defined as the Minimum Price under Nasdaq Listing Rule 5635(d)) as of the date of the Streeterville Exchange Agreement, in exchange for the surrender of the March 2021 Royalty Interest by Streeterville (the “CVP Exchange Transaction”).”
Jaguar Health, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).
“February 15, 2024, the Company received a letter from the Staff notifying the Company that as of February 14, 2024, the Company's common stock had a closing bid price of $0.10 or less for 10 consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As a result, the Staff has issued a letter notifying the Company of its determination to delist the Company’s securities from Nasdaq effective as of the opening of business on February 26, 2024, unless the Company requests an appeal before”
Jaguar Health, Inc. amended Second Amendment to the Office Lease Agreement with M & E, LLC valued at modified expiration for Suite 400 to August 31, 2030; monthly base rental ranging from $39,270.89 to (effective 2023-10-25).
“On October 25, 2023, the Company entered into a Second Amendment to the Lease (the “Second Amendment”), which, among other things, modified the date of expiration for one of the suites covered under the Lease from February 28, 2025 to August 31, 2030.”
Jaguar Health, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“November 8, 2023, Jaguar Health, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until May 6, 2024, to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publ”
Jaguar Health, Inc.: Filed Certificate of Designation for Series I Convertible Preferred Stock, effective September 29, 2023 (effective 2023-09-29).
“the Company agreed to issue shares of Series I Preferred Stock to Uptown. The preferences, rights, limitations and other matters relating to the Series I Preferred Stock are set forth in the Certificate of Designation.”
Jaguar Health, Inc. entered into Exchange Agreement with Uptown Capital, LLC valued at $1,500,000.00 (effective 2023-09-29).
“On September 29, 2023, the Company entered into a privately negotiated exchange agreement with Uptown (the “Exchange Agreement”), pursuant to which the Company issued an aggregate of 118 shares of the Company’s newly authorized Series I Convertible Preferred Stock (the “Series I Preferred Stock”) to Uptown, at an effective exchange price per share equal to the market price (defined as the Minimum Price under Nasdaq Listing Rule 5635(d)) as of the date of the Exchange Agreement, in exchange for a $1,500,000.00 reduction in the outstanding balance of the December 2020 Royalty Interest (the “Exchange Transaction”).”
Jaguar Health, Inc. amended Royalty Interest Global Amendments with Iliad Research and Trading, L.P., Uptown Capital, LLC, Streeterville Capital, LLC valued at $12 million (effective 2023-09-29).
“On September 29, 2023, Jaguar Health, Inc. (the “Company”) entered into amendments (the “Royalty Interest Global Amendments”) to (i) the royalty interest in the original principal amount of $12 million (the “October 2020 Royalty Interest”) with Iliad Research and Trading, L.P. (“Iliad”), as amended, (ii) the royalty interest in the original principal amount of $12 million (the “December 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), as amended, and (iii) the royalty interest in the original principal amount of $12 million (the “August 2022 Royalty Interest” and, together with the October 2020 Royalty Interest and the December 2020 Royalty Interest, the “Royalty Interests”) with Streeterville Capital, LLC (“Streeterville” and, together with Iliad and Uptown, the “Investors”), pursuant to which, beginning on January 1, 2026, the monthly Royalty Payment under each of the Royalty Interests shall be the greater of (a) $750,000.00, and (b) the ac”
Jaguar Health, Inc. reported second quarter 2023 results: revenue approximately $2.7 million.
“was approximately $2.7 million in the second quarter of 2023”
Jaguar Health, Inc. shareholders approved Grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes to approve Proposal 3 and/or Proposal 4. at the 2023-07-07 meeting.
“5. Proposal to approve a proposal to grant discretionary authority to adjourn the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3 and/or Proposal 4, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 5,820,111 339,795 106,198 2,573,182”
Jaguar Health, Inc. shareholders approved Approval of an amendment and restatement of the Company's 2014 Stock Incentive Plan to increase the number of authorized shares by 2,700,000 and extend the remaining term to ten years. at the 2023-07-07 meeting.
“4. Proposal to approve an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan by 2,700,000 shares and extend the remaining term of the 2014 Plan to ten years, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 5,757,091 410,930 98,083 2,573,182”
Jaguar Health, Inc. shareholders approved Approval of the issuance of shares of common stock issuable upon exercise of warrants and conversion of preferred stock issued and to be issued to certain accredited investors in accordance with Nasdaq Listing Rule 5635(d). at the 2023-07-07 meeting.
“3. Proposal to approve the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”), issuable upon exercise of warrants and conversion of preferred stock issued and to be issued to certain accredited investors in accordance with Nasdaq Listing Rule 5635(d), was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 3,028,490 475,340 107,274 2,573,182”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.